Drug Profile
Tarenflurbil
Alternative Names: R-Flurbiprofen; E-7869; Flurizan; MPC-7869; TMP-001; TruNocLatest Information Update: 11 Mar 2019
Price :
$50
*
At a glance
- Originator Loma Linda University Medical Center
- Developer Fraunhofer Institute for Molecular Biology and Applied Ecology; Horizon Pharma AG; Myriad Pharmaceuticals
- Class Antidementias; Antineoplastics; Biphenyl compounds; Propionic acids; Small molecules
- Mechanism of Action Amyloid precursor protein secretase modulators; NF-kappa B inhibitors; Transcription factor AP-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Multiple sclerosis
- Discontinued Alzheimer's disease; Inflammation; Pain; Prostate cancer
Most Recent Events
- 11 Mar 2019 Tarenflurbil is still in phase II trials for Multiple Sclerosis in Germany (NCT02686788)
- 16 Jul 2015 Phase-II clinical trials in Multiple sclerosis (Relapsing, remitting) in Germany (PO) (EudraCT2014-004483-38)
- 23 Mar 2012 Discontinued - Preclinical for Inflammation in Switzerland (PO)